Gout

The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.

Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.

Investigators identified novel biomarkers of incident gout and replicated novel metabolomic biomarkers of gout, including plasma levels of glycoprotein acetyls.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 19, 2022.

Differences among baseline clinical and laboratory characteristics between cases and controls were observed in those with a presence of subcutaneous tophi and higher serum urate levels.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2022.

Dr. Eliseo Pascual's presentation at EULAR 2022 serves as a reminder to consider gender bias during the diagnosis, treatment, and management of rheumatic diseases.

John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.

While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 16, 2022.

“Understanding the drivers of this increased risk in women with gout warrants further investigation in larger datasets," investigators stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 9, 2022.

Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2022.

Supported self-management approaches have been shown to benefit patients with chronic health conditions, including gout.

“The effects of coffee consumption on SUA levels and gout risk are controversial,” investigators explained. “There have hitherto been no reports based on its effects that consider pleiotropy.”

Contrary to recent research that indicated a higher risk of death associated with escalating doses of allopurinol for chronic kidney disease, investigators announce no association between allopurinol initiation and increased mortality among patients with gout and CKD.

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.

Jeff Peterson, MD, discusses his study determining the complete response rate of pegloticase in conjunction with methotrexate.

New ACR findings supporting rheumatology societies' advocacy for more intensive therapy strategies, with proof of safety.

Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”

Investigators analyzed comorbidities, such as diabetes, which has been historically associated with gout, to determine what role, if any, they played in increasing the risk of lower extremity amputation.

Aaron Broadwell, MD, discusses his upcoming ACR study entitled, “Concomitant immunomodulation and pegloticase therapy: experiences with a variety of immunomodulatory agents in two community rheumatology practices.”